Core Insights - Daxor Corporation is expanding its blood volume analysis (BVA) technology into three new hospitals, highlighting the increasing recognition of BVA's role in improving patient outcomes and reducing healthcare costs [1][2] - The growth is attributed to the integration of Daxor's CLIA-certified ezBVA Lab service and on-site blood volume analyzers, which are expected to drive accelerated sales growth throughout 2025 as clinicians adopt BVA for fluid management [1][2] Company Overview - Daxor Corporation is a leader in blood volume measurement technology, known for its BVA-100, the only FDA-cleared diagnostic blood test for quantifying blood volume status and composition [3] - Over 65,000 tests have been conducted at major hospital centers in the U.S., significantly impacting surgical and medical conditions, particularly in reducing mortality and readmissions in heart failure and critical care [3] - The company is involved in ongoing trials for heart failure treatment with NIH support and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [3] Recent Developments - Recent sales wins include the adoption of ezBVA Lab services in a Tennessee medical center for cardiology applications, integration of BVA with an on-site analyzer in an Arkansas hospital for advanced heart care, and utilization of ezBVA Lab service in a leading referral hospital serving Arizona, Nevada, and Utah for advanced heart failure patients [5]